# To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema

> **NCT04058067** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 266 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Brolucizumab
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT04058067
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-23
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058067, "To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04058067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*